Italia Markets closed

Abeona Therapeutics Inc. (0H7R.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,3700+0,0180 (+0,77%)
Alla chiusura: 01:54PM GMT
Schermo intero
Chiusura precedente2,3520
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume1.690
Media VolumeN/D
Capitalizzazione66,211M
Beta (5 anni mensile)1,18
Rapporto PE (ttm)N/D
EPS (ttm)-0,9090
Prossima data utili29 mar 2023 - 03 apr 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

    NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the inaugural International Societies for Investigative Dermatology (ISID) Meeting, being held May 10-13, 2023 in Tokyo, Japan. Abeona previously reported positive top-line efficacy and safety data from the VIITAL s

  • GlobeNewswire

    Abeona Therapeutics Announces Update on AAV Ophthalmology Program

    Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (ADOA) To submit first pre-Investigational New Drug (IND) application meeting request this month NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from

  • GlobeNewswire

    Abeona Therapeutics Reports Third Quarter 2022 Financial Results

    Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway into 3Q 2024 NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022. “The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101’s potential and validation of t